Clinical development plan
We focus on delivering transformative treatment for chronic wounds where there is little to no pharmacologically active treatment available today.
We have shown in a number of investigator-led studies that treatment with plasminogen can heal chronic wounds where little progress had been made with traditional care.
For our initial clinical proof-of-concept studies we will focus on wound healing in diabetic patients. Diabetic patients are a patient group that has an impaired wound healing capacity where development of chronic wounds is a common and disabling complication. Diabetic wounds with impaired healing capacity are the most severe types of chronic wounds that every year affect millions of people. At present, there is no biologically active treatment on the market that accelerates the healing of diabetic wounds that is widely used.